Latest Vancomycin-resistant enterococcus Stories
A new research study of the effect of a commonly used strategy to reduce the spread of antibiotic-resistant bacteria in hospital intensive care units (ICU) shows that the strategy had no significant effect.
A new study from Rhode Island Hospital has found a reduced risk of hospital-acquired infections (HAI) when using two percent chlorhexidine gluconate (CHG) cloths for daily bathing instead of soap and water.
CHAPEL HILL, N.C., Dec.
SUNNYVALE, Calif., April 7 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) will initiate European launch of its newest addition to the GeneXpertÂ® family of molecular diagnostic testing systems, the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria.
HAYWARD, Calif. and SHANGHAI, April 6 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc.
NEW YORK, March 22 /PRNewswire/ -- Recent clinical tests demonstrate that antimicrobial copper is effective in significantly reducing the bacterial load in intensive care unit (ICU) patient rooms and on many individual objects in those rooms. Results from a U.S.
DURHAM, N.C., March 11 /PRNewswire/ -- bioMerieux - a world leader in the field of in vitro diagnostics - today announced the launch of the first Food and Drug Administration (FDA) cleared chromID(TM) VRE, a simple and cost-effective solution in the struggle against vancomycin-resistant enterococci (VRE).
SUNNYVALE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S.
SAN FRANCISCO, Jan. 5 /PRNewswire-FirstCall/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI.OB) announces that its third round of testing and data logging for the enhanced AsepticSure(TM) technology is now complete.
Enterococcus is a Gram-positive, commensal bacterium inhabiting the gastrointestinal tracts of humans and other mammals. It is a main constituent of some probiotic food supplements. E. faecalis can cause life-threatening infections in humans, especially in the nosocomial environment, where the naturally high levels of antibiotic resistance found in E. faecalis contribute to its pathogenicity. It is frequently found in root canal-treated teeth in prevalence values ranging from 30% to 90% of...